Jun 17, 2020
Hepcidin Mimetic PTG-300 Receives U.S. FDA Orphan Drug Designation for the Treatment of Polycythemia Vera
Jun 04, 2020
Protagonist Therapeutics to Present at the 25th European Hematology Association (EHA) Annual Congress
May 07, 2020
Protagonist Therapeutics Reports First Quarter Financial Results and Provides Corporate Update
May 07, 2020
Protagonist Therapeutics Announces Initial Phase 2 Results with Hepcidin Mimetic PTG-300 in the Treatment of Polycythemia Vera
Jan 28, 2020
John Quisel, JD, PhD Joins Disc Medicine as President and Chief Executive Officer
Jan 06, 2020
Protagonist Therapeutics Initiates Phase 2 Study of Novel Hepcidin Mimetic PTG-300 in the Treatment of Patients with Hereditary Hemochromatosis
Dec 03, 2019
Protagonist Therapeutics Announces Preliminary Phase 2 Results with Hepcidin Mimetic PTG-300 in the Treatment of Transfusion Dependent Beta-Thalassemia
Oct 30, 2019
Protagonist Therapeutics Initiates Phase 2 Study of Novel Hepcidin Mimetic PTG-300 in the Treatment of Patients with Polycythemia Vera
Oct 29, 2019
Disc Medicine Expands Pipeline Focused on Hepcidin Pathway
Oct 29, 2019
Disc Medicine Completes $50 Million Series A Financing led by Novo Holdings A/S to Advance New Therapies Addressing Ineffective Red Blood Cell Production
Aug 07, 2019
Protagonist Therapeutics Reports Second Quarter 2019 Financial Results
Jan 16, 2019
Protagonist Therapeutics Reports Granting of Inducement Award
Jan 09, 2019
Protagonist Therapeutics Initiates Phase 2 Trial of Novel Hepcidin Mimetic PTG-300 for the Treatment of Patients with Beta Thalassemia
Nov 07, 2018
Protagonist Therapeutics to Present at the Stifel 2018 Healthcare Conference Wednesday, Nov. 14
Nov 06, 2018
Protagonist Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update
Nov 01, 2018
Sierra Oncology to Report Clinical Data at ASH 2018 from Translational Biology Study of Momelotinib in Transfusion Dependent Patients
Oct 08, 2018
Protagonist Therapeutics Announces Acceptance of Late Breaking Abstract for PTG-100 at the United European Gastroenterology Week Meeting
Sep 24, 2018
Protagonist Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference Monday, Oct. 1
Sep 06, 2018
Protagonist Therapeutics Receives $1.45 Million SBIR Funding for the Development of PTG-300
Sep 06, 2018
Protagonist Therapeutics Expands Intellectual Property Portfolio